QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 reported-earlier-biovie-prices-12m-public-offering-of-6m-units-consisting-of-common-stock-and-warrants-at-200-per-unit

Each unit is being sold to the public at a price of $2.00 per unit (and each pre-funded unit is being sold to the public at the...

 biovie-to-implement-1-for-10-reverse-stock-split-effective-july-7-2025

- SEC Filing

 biovie-to-present-patient-centric-design-and-accessibility-of-ongoing-sunrise-pd-phase-2-clinical-trial-at-advanced-therapeutics-in-movement--related-disorders-congress

BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug ther...

 biovie-enrolls-first-patient-in-phase-2-address-lc-clinical-trial-evaluating-bezisterim-for-treatment-of-neurological-symptoms-associated-with-long-covid-expects-topline-data-to-be-available-in-h1-2026

Despite growing recognition of long COVID as a serious condition, diagnosed patients have no approved treatment options, with m...

 biovie-announces-it-will-present-rationale-and-design-of-phase-2-sunrise-pd-clinical-trial-at-30th-world-congress-on-parkinsons-disease-and-related-disorders-may-7-10-2025-in-new-york-city

BioVie Inc., (NASDAQ:BIVI) ("BioVie" or the "Company") a clinical-stage company developing innovative drug ther...

 biovie-opens-patient-enrollment-for-phase-2-sunrise-pd-clinical-trial-evaluating-the-safety-and-efficacy-of-bezisterim-on-motor-and-non-motor-symptoms-in-patients-with-parkinsons-disease-who-havent-been-treated-with-carbidopalevodopa-topline-data-expected-in-late-2025-or-early-2026

SUNRISE-PD evaluating the Company's anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson&...

 biovie-to-present-design-of-planned-phase-2-study-of-bezisterim-for-the-treatment-of-long-covid-at-the-demystifying-long-covid-international-conference

BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug the...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION